Approval · Notice of Compliance 37309 · 2026
TABRECTA: Notice of Compliance 37309
Issued April 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37309
- Date
- April 9, 2026
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug product manufacturing site and/or manufacturer involving production. Change in the drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TABRECTA | Not yet assigned | — |
Medicinal ingredients
- CAPMATINIB HYDROCHLORIDE 150 MG per TAB
- CAPMATINIB HYDROCHLORIDE 200 MG per TAB